復方丹參注射液聯(lián)合伊馬替尼對急性淋巴細胞白血病患者P-糖蛋白、P53蛋白水平及心血管功能的影響
發(fā)布時間：2018-11-25 09:22
【摘要】：目的:探討復方丹參注射液聯(lián)合伊馬替尼對急性淋巴細胞白血病(ALL)患者P-糖蛋白、P53蛋白水平及心血管功能的影響。方法:隨機數(shù)字表格法將納入標準的80例ALL患者分為對照組與觀察組,各40例,所有患者均接受VDCP化療方案治療,此外對照組加以伊馬替尼治療,觀察組則加以復方丹參注射液聯(lián)合伊馬替尼治療,比較兩組近期療效、不良反應、治療前后外周血象、免疫功能及心率變異性(HRV)指標,同時治療前后通過流式細胞儀測定P-糖蛋白及P53蛋白水平。結果:觀察組治療有效率90.00%,較對照組的80.00%差異無統(tǒng)計學意義(P0.05)。與治療前比較,治療后兩組WBC水平顯著下降,Hb、PLT、RBC水平顯著上升(P0.05)。觀察組治療后WBC、Hb、RBC、CD_3~+、CD_4~+、CD_4~+/CD_8~+、SDNN、SDANN、RMSSD、PNN50水平均明顯高于對照組(P0.05)。觀察組治療后P53陽性表達率較治療前明顯下降,較對照組明顯低(P0.05)。觀察組肝功能異常發(fā)生率明顯低于對照組(P0.05)。結論:復方丹參注射液聯(lián)合伊馬替尼治療ALL療效明確,能有效減少伊馬替尼+化療不良反應,降低P-糖蛋白及P53蛋白陽性表達率,且對患者免疫功能、心率變異性有一定的改善作用。
[Abstract]:Aim: to investigate the effects of compound salvia miltiorrhiza injection combined with imatinib on the levels of P glycoprotein, p53 protein and cardiovascular function in patients with acute lymphoblastic leukemia (ALL). Methods: 80 patients with ALL were randomly divided into two groups: control group (n = 40) and observation group (n = 40). All patients were treated with VDCP chemotherapy regimen, and the control group were treated with imatinib. The observation group was treated with compound salvia miltiorrhiza injection combined with imatinib. The short-term curative effect, adverse reaction, peripheral blood picture, immune function and (HRV) index of heart rate variability before and after treatment were compared between the two groups. At the same time, the levels of P-glycoprotein and P 53 protein were measured by flow cytometry before and after treatment. Results: the effective rate of treatment in the observation group was 90.00%, which was not significantly different from that in the control group (80.00%) (P0.05). Compared with before treatment, the level of WBC decreased significantly and the level of Hb,PLT,RBC increased significantly in the two groups after treatment (P0.05). The levels of WBC,Hb,RBC,CD_3~, CD_4~, CD_4~ / CD_8~ and SDNN,SDANN,RMSSD,PNN50 in the observation group were significantly higher than those in the control group (P0.05). After treatment, the positive expression rate of p53 in the observation group was significantly lower than that in the control group (P0.05). The incidence of abnormal liver function in the observation group was significantly lower than that in the control group (P0.05). Conclusion: compound salvia miltiorrhiza injection combined with imatinib is effective in the treatment of ALL. It can effectively reduce the adverse reaction of imatinib chemotherapy, decrease the positive rate of expression of P-glycoprotein and p53 protein, and can improve the immune function of the patients. Heart rate variability can be improved to some extent.
【作者單位】： 湖州市中醫(yī)院內(nèi)科;
【基金】：浙江省自然科學基金項目(2015348572)
【分類號】：R733.71
[Abstract]:Aim: to investigate the effects of compound salvia miltiorrhiza injection combined with imatinib on the levels of P glycoprotein, p53 protein and cardiovascular function in patients with acute lymphoblastic leukemia (ALL). Methods: 80 patients with ALL were randomly divided into two groups: control group (n = 40) and observation group (n = 40). All patients were treated with VDCP chemotherapy regimen, and the control group were treated with imatinib. The observation group was treated with compound salvia miltiorrhiza injection combined with imatinib. The short-term curative effect, adverse reaction, peripheral blood picture, immune function and (HRV) index of heart rate variability before and after treatment were compared between the two groups. At the same time, the levels of P-glycoprotein and P 53 protein were measured by flow cytometry before and after treatment. Results: the effective rate of treatment in the observation group was 90.00%, which was not significantly different from that in the control group (80.00%) (P0.05). Compared with before treatment, the level of WBC decreased significantly and the level of Hb,PLT,RBC increased significantly in the two groups after treatment (P0.05). The levels of WBC,Hb,RBC,CD_3~, CD_4~, CD_4~ / CD_8~ and SDNN,SDANN,RMSSD,PNN50 in the observation group were significantly higher than those in the control group (P0.05). After treatment, the positive expression rate of p53 in the observation group was significantly lower than that in the control group (P0.05). The incidence of abnormal liver function in the observation group was significantly lower than that in the control group (P0.05). Conclusion: compound salvia miltiorrhiza injection combined with imatinib is effective in the treatment of ALL. It can effectively reduce the adverse reaction of imatinib chemotherapy, decrease the positive rate of expression of P-glycoprotein and p53 protein, and can improve the immune function of the patients. Heart rate variability can be improved to some extent.
【作者單位】： 湖州市中醫(yī)院內(nèi)科;
【基金】：浙江省自然科學基金項目(2015348572)
【分類號】：R733.71
【參考文獻】
相關期刊論文 前7條
1 劉奎;郭sヂ，
本文編號：2355601
本文鏈接：http://www.sikaile.net/yixuelunwen/zlx/2355601.html
最近更新
教材專著
